Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Reuters

11/13

Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Overview

Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations
Company's operating expenses increased to $42.8 mln in Q3 2025
Celcuity on track to submit NDA for gedatolisib in Q4 2025

Outlook

Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026
Celcuity plans to submit NDA for gedatolisib in Q4 2025

Result Drivers

FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Adjusted EPS	Beat	-$0.78	-$1.02 (7 Analysts)
Q3 EPS		-$0.92
Q3 Adjusted Net Income	Beat	-$37.20 mln	-$43 mln (7 Analysts)
Q3 Net Income		-$43.80 mln
Q3 Operating Expenses		$42.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17

Press Release: ID:nGNX9HLwC2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583588271"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583588271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583588271?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583588271","market":"us","top_or_hot":-1,"title":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share </title></head><body><p><span>Overview</span></p><ul><li><p>Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations</p></li><li><p>Company's operating expenses increased to $42.8 mln in Q3 2025</p></li><li><p>Celcuity on track to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Celcuity plans to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.78</p></td><td><p>-$1.02 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.92</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.20 mln</p></td><td><p>-$43 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$43.80 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $78.00, about 1.5% below its November 11 closing price of $79.17</p></li></ul><p>Press Release: <span>ID:nGNX9HLwC2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-13 05:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share </title></head><body><p><span>Overview</span></p><ul><li><p>Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations</p></li><li><p>Company's operating expenses increased to $42.8 mln in Q3 2025</p></li><li><p>Celcuity on track to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Celcuity plans to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.78</p></td><td><p>-$1.02 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.92</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.20 mln</p></td><td><p>-$43 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$43.80 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $78.00, about 1.5% below its November 11 closing price of $79.17</p></li></ul><p>Press Release: <span>ID:nGNX9HLwC2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO12O:1","article_id":"2583588271","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583588271","pubTimestamp":1762981905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per shareOverviewCelcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectationsCompany's operating ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc","BK4139":"生物科技"},"translate_title":"癌症诊断公司Celcuity公布第三季度调整后每股亏损低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share OverviewCelcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectationsCompany's operating expenses increased to $42.8 mln in Q3 2025Celcuity on track to submit NDA for gedatolisib in Q4 2025OutlookCelcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026Celcuity plans to submit NDA for gedatolisib in Q4 2025Result DriversFINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structureKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Adjusted EPSBeat-$0.78-$1.02 (7 Analysts)Q3 EPS-$0.92Q3 Adjusted Net IncomeBeat-$37.20 mln-$43 mln (7 Analysts)Q3 Net Income-$43.80 mlnQ3 Operating Expenses$42.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17Press Release: ID:nGNX9HLwC2For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}